We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aegerion Pharmaceuticals CEO Marc Beer’s televised comments about the company’s heart drug Juxtapid have drawn a warning letter from the FDA for failing to mention drug risks and promoting an off-label use. Read More